US 11,739,068 B2
Polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof
Haydn Beaton, Loughborough (GB); David Malcolm Crowe, Reading (GB); and Hannah Joy Edwards, Wiltshire (GB)
Assigned to KalVista Pharmaceuticals Limited, Porton Down (GB)
Filed by KALVISTA PHARMACEUTICALS LIMITED, Wiltshire (GB)
Filed on Oct. 20, 2021, as Appl. No. 17/505,906.
Application 17/505,906 is a continuation of application No. 16/303,334, granted, now 11,230,537, previously published as PCT/GB2017/051579, filed on Jun. 1, 2017.
Claims priority of provisional application 62/344,059, filed on Jun. 1, 2016.
Claims priority of application No. 1609607 (GB), filed on Jun. 1, 2016.
Prior Publication US 2022/0041571 A1, Feb. 10, 2022
Int. Cl. C07D 401/02 (2006.01)
CPC C07D 401/02 (2013.01) [C07B 2200/13 (2013.01)] 13 Claims
 
1. A method of treating a disease or condition mediated by plasma kallikrein in a mammal in need of such treatment, said method comprising administering to the mammal a therapeutically effective amount of a crystalline form of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide, wherein the N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide is crystalline form 1 of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide, which exhibits at least X-ray powder diffraction peaks (Cu Kα radiation, expressed in degrees 2θ) at 11.2±0.3, 12.5±0.3, 13.2±0.3, 14.5±0.3, and 16.3±0.3 and/or exhibits an endothermic peak in its DSC thermograph at 151±3° C.